Patents by Inventor Eileen R. Mulvihill

Eileen R. Mulvihill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • L-AP4 sensitive glutamate receptors
    Patent number: 6274330
    Abstract: Metabotropic receptor mGluR7 is identified and sequenced. The mGluR7 receptor subfamily mediates inhibition of transmitter release at selected glutamatergic synapses. The receptors, mGluR7-specific peptides and antibodies thereto are used to identify agonists and antagonists of G protein coupled glutamate receptor mediated neuronal transmitter release, as well as in methods of diagnosis and therapy.
    Type: Grant
    Filed: December 30, 1993
    Date of Patent: August 14, 2001
    Assignees: ZymoGenetics, Inc., State of Oregon, acting by and through the Oregon State Board of Higher Education on behalf of the Oregon Health Sciences University
    Inventors: Thomas P. Segerson, J. Mark Kinzie, Eileen R. Mulvihill, Julie A. Saugstad, Gary L. Westbrook
  • Oligonucleotide probes to L-AP4 sensitive glutamate receptor sequences
    Patent number: 5831047
    Abstract: Metabotropic receptor mGluR7 is identified and sequenced. The mGluR7 receptor subfamily mediates inhibition of transmitter release at selected glutamatergic synapses. The receptors, mGluR7-specific peptides and antibodies thereto are used to identify agonists and antagonists of G protein coupled glutamate receptor mediated neuronal transmitter release, as well as in methods of diagnosis and therapy.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: November 3, 1998
    Assignees: ZymoGenetics, Inc., State of Oregon, acting by and through the Oregon State Board of Higher Education on behalf of the Oregon Health Sciences University
    Inventors: Thomas P. Segerson, J. Mark Kinzie, Eileen R. Mulvihill, Julie A. Saugstad, Gary L. Westbrook
  • L-AP4 sensitive glutamate receptors
    Patent number: 5738999
    Abstract: Metabotropic receptor mGluR7 is identified and sequenced. The mGluR7 receptor subfamily mediates inhibition of transmitter release at selected glutamatergic synapses. The receptors, mGluR7-specific peptides and antibodies thereto are used to identify agonists and antagonists of G protein coupled glutamate receptor mediated neuronal transmitter release, as well as in methods of diagnosis and therapy.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: April 14, 1998
    Assignees: ZymoGenetics, Inc., State of Oregon, acting by and through the Oregon State Board of Higher Education on behalf of the Oregon Health Sciences University
    Inventors: Thomas P. Segerson, J. Mark Kinzie, Eileen R. Mulvihill, Julie A. Saugstad, Gary L. Westbrook
  • Co-expression in eukaryotic cells
    Patent number: 5648254
    Abstract: A method of producing proteins of interest is disclosed. The method includes the introduction of a first DNA sequence encoding the protein of interest and at least one additional DNA sequence encoding a protein which processes or stabilizes the protein of interest into a eukaryotic host cell. The host cell is subsequently cultured under conditions which allow the DNA sequences to be expressed. Suitable eukaryotic hosts include mammalian cells and yeast cells.
    Type: Grant
    Filed: July 14, 1994
    Date of Patent: July 15, 1997
    Assignee: ZymoGenetics, Inc.
    Inventors: Eileen R. Mulvihill, A. Ashok Kumar
  • Tissue plasminogen activator analogs having modified growth factor domains
    Patent number: 5486471
    Abstract: Tissue plasminogen activator analogs containing the growth factor domain of native t-PA, the domain having at least one cysteine residue replaced with another amino acid. The t-PA analogs may further contain a variety of substitutions and/or modifications. Pharmaceutical compositions containing one or more of the t-PA analogs along With a physiologically acceptable carrier or diluent are also disclosed.
    Type: Grant
    Filed: March 6, 1995
    Date of Patent: January 23, 1996
    Assignee: ZymoGenetics, Inc.
    Inventors: Eileen R. Mulvihill, Shinji Yoshitake, Yasunori Ikeda, Suguru Suzuki, Akira Hashimoto, Teruaki Yuzuriha, Bjorn A. Nexo
  • t-PA with growth factor domain substitutions
    Patent number: 5403734
    Abstract: A plasminogen activator comprising a growth factor domain, a kringle domain and a serine protease domain is disclosed. The growth factor domain contains a plurality of substitutions of substantially consecutive amino acids as compared to the growth factor domain of native t-PA, the substitutions resulting in an increase in plasma half-life.
    Type: Grant
    Filed: October 15, 1991
    Date of Patent: April 4, 1995
    Assignee: ZymoGenetics, Inc.
    Inventors: Eileen R Mulvihill, Patrick J. O'Hara
  • Method for producing a mammalian G protein coupled glutamate receptor
    Patent number: 5385831
    Abstract: Mammalian G protein coupled glutamate receptors are identified, isolated and purified. The receptors have been cloned, sequenced and expressed by recombinant means. The receptors and antibodies thereby may be used to identify agonists and antagonists of G protein coupled glutamate receptor mediated neuronal excitation, as well as in methods of diagnosis.
    Type: Grant
    Filed: April 1, 1993
    Date of Patent: January 31, 1995
    Assignees: Zymogenetics, Inc., The Board of Regents of the University of Washington
    Inventors: Eileen R. Mulvihill, Frederick S. Hagen, Khaled M. Houamed, Wolfhard Almers
  • Thrombin-activated tissue plasminogen activators
    Patent number: 5200340
    Abstract: Zymogens of proteins having fibrinolytic activity are disclosed. The proteins are cleavable by thrombin, the cleavage resulting in the stimulation of fibrinolytic activity. Suitable proteins which may be modified in accordance with the present invention include tissue plasminogen activator, urokinase, and plasminogen variants. The modified molecules are substantially clot-specific, in view of the large amounts of thrombin associated with clots in vivo.
    Type: Grant
    Filed: May 22, 1987
    Date of Patent: April 6, 1993
    Assignee: ZymoGenetics, Inc.
    Inventors: Donald C. Foster, Eileen R. Mulvihill, Patrick J. O'Hara, Kurt Pingel, Shinji Yoshitake
  • Modified t-PA with kringle-/replaced by another kringle
    Patent number: 5149533
    Abstract: Tissue plasminogen activator analogs exhibiting greater specificity for fibrin than native t-PA are disclosed. The analogs include the K1 domain of native t-PA replaced with another kringle domain mediating the binding of the analog to fibrin. The kringle contains six cysteine residues. The t-PA analogs may further include a variety of substitutions and modifications. Pharmaceutical compositions containing one or more of the t-PA analogs along with a physiologically acceptable carrier or diluent are also disclosed.
    Type: Grant
    Filed: August 12, 1991
    Date of Patent: September 22, 1992
    Assignee: ZymoGenetics, Inc.
    Inventors: Eileen R. Mulvihill, Shinji Yoshitake, Yasunori Ikeda, Suguru Suzuki, Akira Hashimoto, Teruaki Yuzuriha, Bjorn A. Nexo